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Abstract
Prior studies have reported the presence of lung ﬁbrosis and enhanced airway hyperresponsiveness (AHR) in mice with
high-fat-diet (HFD)-induced obesity. This study evaluated the role of TGF-β1 in HFD-induced AHR and lung ﬁbrosis in a
murine model. We generated HFD-induced obesity mice and performed glucose and insulin tolerance tests. HFD mice
with or without ovalbumin sensitization and challenge were also treated with an anti-TGF-β1 neutralizing antibody.
AHR to methacholine, inﬂammatory cells in the bronchoalveolar lavage ﬂuid (BALF), and histological features were
evaluated. Insulin was intranasally administered to normal diet (ND) mice, and in vitro insulin stimulation of BEAS-2b
cells was performed. HFD-induced obesity mice had increased insulin resistance, enhanced AHR, peribronchial and
perivascular ﬁbrosis, and increased numbers of macrophages in the BALF. However, they did not have meaningful
eosinophilic or neutrophilic inﬂammation in the lungs compared with ND mice. The HFD enhanced TGF-β1 expression
in the bronchial epithelium, but we found no differences in the expression of interleukin (IL)−4 or IL-5 in lung
homogenates. Administration of the anti-TGF-β1 antibody attenuated HFD-induced AHR and lung ﬁbrosis. It also
attenuated goblet cell hyperplasia, but did not affect the AHR and inﬂammatory cell inﬁltration induced by OVA
challenge. The intranasal administration of insulin enhanced TGF-β1 expression in the bronchial epithelium and lung
ﬁbrosis. Stimulating BEAS-2b cells with insulin also increased TGF-β1 production by 24 h. We concluded that HFD-
induced obesity-associated insulin resistance enhances TGF-β1 expression in the bronchial epithelium, which may play
an important role in the development of lung ﬁbrosis and AHR in obesity.
Introduction
In the last decade, the number of diagnosed asthma
patients has increased to over 300 million people world-
wide1. Recent studies have demonstrated that obesity is an
important causative factor of asthma, and that the risk of
asthma is doubled in obese patients compared with nor-
mal weight patients2,3. Furthermore, a decrease in body
weight improves asthma outcomes4. As the proportion of
people with obesity is steadily increasing, the burden of
obesity on asthma is also becoming increasingly impor-
tant5. Obesity-associated asthma differs from none
obesity-associated asthma in several ways, speciﬁcally,
patients with obesity-associated asthma struggle with
poor asthma control and are frequently resistant to con-
ventional treatments6,7.
However, the mechanism underlying the association
between obesity and asthma remains controversial. Obe-
sity itself is associated with increases in the levels of
various systemic proinﬂammatory mediators, such as C-
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reactive protein (CRP), leptin, and interleukin (IL)−68–10.
High-fat-diet (HFD)-induced obesity may also induce
increased levels of IL-1β, tumor necrosis factor (TNF)-α,
IL-17, and transforming growth factor (TGF)-β in lung
tissue11–14. We previously demonstrated that a HFD is
signiﬁcantly associated with AHR and lung ﬁbrosis in
mice with TNF-α-producing macrophages, but not with
enhanced accumulation of eosinophils or neutrophils in
the lung tissue, and the enhancement in AHR was
eliminated by treating the obese mice with exercise4,8,11.
The association between AHR and lung ﬁbrosis without
allergic inﬂammation in HFD-induced obesity indicates a
causal relationship between airway remodeling and the
development of AHR in this model.
TGF-β, an adipokine, has diverse roles in the main-
tenance of cellular homeostasis, lung development, and
physiology15. TGF-β stimulates the production of con-
nective tissue by ﬁbroblasts, and enhanced expression of
TGF-β in the lungs may induce tissue dysfunctions, such
as the lung ﬁbrosis and airway remodeling seen in asthma
and chronic bronchitis15–17. TGF-β can be secreted by
epithelial cells, ﬁbroblasts, eosinophils, mast cells, and
Treg cells17. Several cytokines and chemokines related to
allergic inﬂammation, such as IL-13, adenosine, VEGF,
and CCR2, stimulate the production of TGF-β1 from
these cells18. However, in addition to the TGF-β1 path-
way, other mechanisms, such as the IL-13 and periostin
pathway, also engage in the development of subepithelial
ﬁbrosis in the lungs and airway remodeling of asthma19.
Recent studies have shown that TGF-β1 expression is also
enhanced by HFD-induced obesity in mice12,13,20 and
Drosophila21. Furthermore, insulin resistance is a critical
problem in obesity and is associated with proin-
ﬂammatory reactions involving various immune cells and
cytokines22. Some studies have reported that TGF-β is
associated with insulin resistance21,23, and that blocking
TGF-β signaling protects against the development of
HFD-induced obesity and diabetes in mice24. In vitro
experiments have demonstrated that cells from insulin-
resistant subjects and bronchial cells treated with insulin
exhibit increased TGF-β activation and subsequently
increased lung ﬁbrosis25,26. These ﬁndings suggest that
TGF-β1 might be the connection between airway remo-
deling and AHR in obesity-associated asthma16. However,
the role of TGF-β1 may be complicated as some investi-
gators have also reported that TGF-β1 has anti-
inﬂammatory effects on allergic asthma27.
In this study, we hypothesized that the insulin resistance
or increased insulin levels in obesity might play a sig-
niﬁcant role in obesity-induced airway hyperresponsive-
ness and lung ﬁbrosis via the TGF-β1 pathway. Therefore,
we evaluated whether insulin resistance and TGF-β1
production affect HFD-induced AHR and lung ﬁbrosis
using a murine model.
Materials and methods
Animals
Male C57BL/6 mice were purchased from Japan-SLC
(Hamamatsu, Japan). The study scheme for this study is
shown in Fig. 1, and was approved by the Institutional
Animal Care and Use Committee of Yonsei University
College of Medicine (IACUC number: 2017-0349). Each
group consisted of four mice, and all mice were main-
tained under standard conditions (room temperature of
21–24 °C, relative humidity of 45–70%, and a 12-h light/
dark cycle) at conventional animal facilities, which were
fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International.
Feeding
All mice were fed a normal diet (ND) or HFD for
12 weeks. The ND (D12450B; Research Diets Inc., New
Brunswick, NJ, USA) contained 10% kcal from fat, and the
HFD (D12492; Research Diets Inc.) contained 60% kcal
from fat. The mice were weighed weekly.
Ovalbumin-induced asthma model
Mice were sensitized with a mixture containing 20 µg of
ovalbumin (OVA; InvivoGen, San Diego, CA, USA) and
Imject Alum (100 µL per mouse; Thermo Fisher Scien-
tiﬁc, Rockford, IL, USA) by intraperitoneal (i.p.) injection
on days 0 and 14. One week after the last injection, the
mice were challenged with OVA (30 µg per mouse) via
intranasal injection on three consecutive days. For intra-
nasal administration, the mice were anesthetized with
isoﬂurane (jw Pharmaceutical, Seoul, Korea). Two days
after the last OVA challenge, the mice were killed for
analysis (Fig. 1).
Glucose and insulin tolerance tests and Insulin
measurement
An oral glucose tolerance test (OGTT) and insulin
tolerance test (ITT) were performed at the 10th and 11th
weeks, respectively, after HFD feeding. Food was withheld
from the mice overnight for the OGTT and withheld for
4 h for the ITT. The OGTT was performed by orally
administering glucose (2 g/kg body weight; Sigma-
Aldrich, St. Louis, MO, USA). For the ITT, the mice were
administered insulin (2 U/kg body weight; Sigma-Aldrich)
by i.p. injection. The blood glucose level was measured in
OVA Sensitization
OVA Challenge
TGF-
Fig. 1 Study scheme. ND normal diet, HFD high-fat-diet, OVA
ovalbumin
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blood collected from the tail vein at 0, 30, 60, 90, and
120min after glucose or insulin injection using blood
glucose strips and an Accu-Check glucometer (Roche,
Mannheim, Germany). Mouse insulin concentrations
were measured after 12-h fasting and feeding states using
an ELISA kit (Alpco, Salem, NH, USA).
Anti-TGF-β1-blocking antibody studies
To block TGF-β1, a rabbit anti-mouse TGF-β neu-
tralizing mAb (100 µg/mouse; R&D Systems Inc., Min-
neapolis, MN, USA) or rabbit IgG antibody (100 µg/
mouse; R&D Systems) was administered once via the
intravenous (i.v.) route 4 h before the ﬁrst OVA challenge
(Fig. 1).
Measurement of methacholine airway
hyperresponsiveness
Mice were anesthetized with pentobarbital sodium
(50 mg/kg; Hanlim Pharma Co., Seoul, Korea) by i.p.
injection at 48 h after the last challenge. An 18-gauge
cannula was inserted into the anesthetized mice via tra-
cheostomy, and then the mice were connected to a ven-
tilator. AHR in response to various concentrations of
inhaled aerosolized methacholine (MCh) (6.25, 12.5, 25.0,
50.0, and 100.0 mg/ml; Sigma-Aldrich) was measured
using a forced oscillation technique (FlexiVent® 5.1;
SCIREQ, Montreal, Canada).
Collection and processing of the bronchoalveolar lavage
ﬂuid
To collect the bronchoalveolar lavage ﬂuid (BALF), the
lungs were irrigated with 1 ml of HBSS (Thermo Fisher
Scientiﬁc, Waltham, MA, USA) through a tracheal tube.
The total number of cells was counted using a hemocyt-
ometer. The collected BALF was centrifuged for 3 min at
10,000 rpm and 4 °C. The whole cells were resuspended in
HBSS, and BALF cell smears were prepared by cytocen-
trifugation (Cytospin 3, Thermo Fisher Scientiﬁc, Bill-
erica, MA, USA). The cytocentrifuged slides were stained
with Leukostat (Fisher Diagnostics, Fair Lawn, NJ, USA),
and at least 200 inﬂammatory cells were counted.
Enzyme-linked immunosorbent assay and lung
homogenates
To analyze cytokine levels, the right lung tissue was
homogenized with 50mg/ml tissue protein extraction
buffer (Thermo Fisher Scientiﬁc, Rockford, IL, USA)
using a tissue homogenizer (Biospec Products, Bartles-
ville, OK, USA). After an incubation for 30 min on ice, the
homogenates were centrifuged at 1000 g for 10 min. The
supernatants of the lung homogenates were collected,
passed through a 0.45-micron ﬁlter (Gelman Science, Ann
Arbor, MI, USA) and stored at −80 °C until cytokine
levels were measured. The measured cytokine levels were
normalized to the lung tissue weight. Concentrations of
IL-4, IL-5, and TGF-β1 in the lung homogenates or cell
supernatants were measured by ELISA (R&D Systems,
San Diego, CA, USA) according to the manufacturer’s
instructions.
Histological analysis
The left lung of mice was ﬁxed in 4% formalin and
embedded in parafﬁn. Lung sections were cut (3–4 -µm
thickness) and stained with hematoxylin and eosin (H&E)
for general examination, periodic acid-Schiff (PAS) to
measure goblet cell hyperplasia, and Masson’s trichrome
(MT) to assess ﬁbrosis. The tissue sections were examined
using an Olympus BX40 microscope in conjunction with
an Olympus U-TV0.63XC digital camera (Olympus
BX53F, Center Valley, PA, USA). Images were acquired
using cellSens Standard 1.6 imaging software. The H&E-
and PAS-stained sections were scored using a semi-
quantitative system. The severity of inﬂammation was
scored as follows: 0, no inﬂammatory cell inﬁltrates; 1,
minimal inﬂammation; 2, mild inﬂammation; 3, moderate
inﬂammation; and 4, robust inﬂammation. Goblet cell
hyperplasia was measured by the number of PAS-positive
cells per 1000 airway epithelial cells. A quantitative ana-
lysis of ﬁbrosis was conducted using Metamorph®
(Molecular Devices, Sunnyvale, CA, USA). The ﬁbrotic
area was assessed by measuring the color-pixel count over
the preset threshold color for the entire ﬁeld containing
several bronchial tubes in MT-stained slides at ×200
magniﬁcation.
Anti-TGF-β1 immunohistochemistry
Parafﬁn blocks were cut into 4-µm sections, depar-
afﬁnized, and rehydrated in xylene and ethanol solutions.
Antigen retrieval was performed with the tissue sections
in a microwave oven using sodium citrate buffer (pH 6.0)
for 10min. The sections were incubated overnight at 4 °C
with an anti-TGF-β antibody (Ab92486, Abcam, Cam-
bridge, UK), followed by incubation with appropriate
biotinylated secondary antibodies (PK-6101, 6105, or
6200; Vector Laboratories, Burlingame, CA, USA). The
immunocomplexes were visualized via 3,3′-diamino-
benzidine (SK-4100; Vector Laboratories) staining.
Hydroxyproline analysis
To measure the collagen content of the lungs, a hydro-
xyproline assay was performed using a commercial
hydroxyproline assay kit (Cell Biolabs Inc., San Diego, CA,
USA). Lung tissue was homogenized in PBS. The homo-
genates were added to an HCl solution and incubated for
3 h at 120 °C. The hydrolysates were centrifuged at 10,000 g
for 3min and transferred to 96-well plates for analysis.
Hydroxyproline levels were assessed with a spectro-
photometer at 560 nm.
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In vivo and in vitro bronchial epithelial cell stimulation
with insulin
We intranasally administered 20 µg of insulin once daily
to C57BL/6 mice for 11 days and killed the mice 24 h after
the last administration. Human bronchial epithelial
BEAS-2B cells were grown and cultured. The BEAS-2B
cells were maintained in bronchoepithelial basal medium
(Lonza, Basel, Switzerland) with supplements in six-well
plates. After reaching 80% conﬂuence, the cells were
treated with two concentrations of insulin (0.1, 1, and
10 µg/ml) for 1, 4, and 24 h. To measure the total TGF-β1
content, the cell supernatant was acidiﬁed with acetic acid
and then neutralized.
Statistical analysis
All results are expressed as the mean ± SEM. One-way
analysis of variance (ANOVA) was performed using SPSS
statistical software version 12.0 (SPSS Inc., Chicago, IL,
USA). The AHR data were analyzed with repeated-
measures ANOVA followed by a post hoc Bonferroni
test. The other data were analyzed with one-way ANOVA
followed by a post hoc Bonferroni test. P < 0.05 was
considered statistically signiﬁcant.
Results
HFD-induced changes in body weight, oral glucose
tolerance, insulin tolerance, and insulin concentration
Body weight in the HFD groups (naive HFD and
OVA-challenged HFD) began to increase from the ﬁrst
week of HFD feeding. At killing during the 12th week,
the mean weight of the mice in the ND groups was
29.2 g, whereas that of the mice in the HFD groups was
47.4 g (Fig. 2a). The ND and HFD groups displayed the
same blood glucose level at baseline. At the 11th week,
the blood glucose levels of the HFD groups were sig-
niﬁcantly higher than those of the ND groups (Fig. 2b).
At 10 weeks of HFD feeding, the mice in the HFD
groups exhibited signiﬁcantly impaired glucose toler-
ance (Fig. 2c) compared with those in the ND groups.
The next week, the insulin tolerance test was per-
formed, and we found that the HFD groups had
impaired insulin tolerance (Fig. 2d). Mouse serum
insulin concentrations after 12-h fasting and feeding
states were also measured during the 12th week of HFD
feeding. Fasting insulin levels were not different
between the ND and HFD groups, but in the feeding
state, the insulin concentration of the HFD groups was
signiﬁcantly higher than that of the ND groups (Fig. 2e).
AHR to MCh, BALF, expression of cytokines, and lung
histological features of HFD mice
We next examined AHR and performed BALF cell
analysis with HFD mice. The AHR to MCh in naive HFD
mice was signiﬁcantly higher than that in naive ND mice
(Fig. 3a). BALF analysis revealed that the HFD did not
induce the inﬁltration of eosinophils, neutrophils, or
lymphocytes, but did increase the number of macro-
phages. The HFD also did not exacerbate allergic
inﬂammation in the BALF of mice with OVA-induced
asthma (Fig. 3b). ND mice with OVA-induced asthma had
high-expression levels of IL-4 and IL-5, but naive HFD
mice did not express signiﬁcantly higher IL-4 or IL-5
levels in the lung tissue than naive ND mice (Fig. 3c, d). In
addition, the OVA-HFD group did not exhibit enhanced
IL-4, IL-5, or TGF-β1 expression compared with the
OVA-ND group. Instead, the naive HFD group exhibited
enhanced TGF-β1 expression in lung homogenates
(Fig. 3e) compared with the naive ND group, and
immunohistochemical staining showed increased expres-
sion of TGF-β1 in naive HFD mice, especially in the
bronchial epithelium (Fig. 3f). We further investigated
whether OVA-induced asthma affected the expression of
TGF-β1 in the lungs of mice but found that OVA chal-
lenge did not affect the protein expression of TGF-β1 in
the bronchial epithelium (Fig. 3f).
Histological changes in lung tissue were evaluated by
H&E, PAS, and MT staining. HFD feeding did not
increase the number of inﬂammatory cells located in the
peribronchial and perivascular areas or the number of
PAS+, mucus-containing, metaplastic goblet cells.
However, MT staining revealed increased peribronchial
and perivascular collagen deposition in the HFD groups
(Fig. 4a). To conﬁrm this histological ﬁnding, we exam-
ined the collagen content of the lung tissue using a
hydroxyproline assay, and the result was consistent with
that observed by MT staining (Fig. 4b).
Inhibition of TGF-β1 ameliorated HFD-induced AHR and
ﬁbrosis
The inhibition of TGF-β1 ameliorated HFD-induced
AHR in naive mice (Fig. 4c). As previously shown, the
HFD did not induce eosinophilic or neutrophilic inﬂam-
mation, but did increase the number of macrophages in
the BALF. Therefore, the inhibition of TGF-β1 in naive
HFD mice had no effects on the inﬂammatory cell fea-
tures of the BALF, except for the attenuation of the
increased number of macrophages (Fig. 4d). We also
evaluated the effects of inhibiting TGF-β1 on lung tissue
histopathology in HFD-induced obesity mice. The inhi-
bition of TGF-β1 in naive HFD mice ameliorated HFD-
induced peribronchial and perivascular ﬁbrosis (Fig. 4a).
Consistently, lung tissue hydroxyproline levels were
attenuated by the administration of the anti-TGF-β1
antibody (Fig. 4b). Taken together, these results indicated
that the inhibition of TGF-β1 ameliorated HFD-induced
ﬁbrosis in the lungs.
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Inhibition of TGF-β1 attenuated goblet cell hyperplasia,
but did not affect OVA-induced AHR and allergic
inﬂammation
To evaluate the differences in AHR and airway inﬂam-
mation induced by obesity and OVA, we examined the
effects of anti-TGF-β mAb administration on the OVA-
induced asthma model in ND and HFD mice (Fig. 5a–d).
As expected, AHR was signiﬁcantly increased in the
OVA-ND mice, but treatment with the anti-TGF-β mAb
did not affect AHR or the inﬂammatory cell proﬁle of the
BALF (Fig. 5a, b). However, the inhibition of TGF-β
attenuated goblet cell hyperplasia in the OVA-ND mice
(Fig. 6a–c). The OVA-HFD mice had more aggravated
AHR and goblet cell hyperplasia in the epithelium
Fig. 2 Physiologic and metabolic changes of studied groups. Comparisons of body weight (a), blood glucose levels (b), the results of an oral
glucose tolerance test (c) performed during the 10th week of HFD feeding, and an insulin tolerance test performed during the 11th week of HFD
feeding (d) between HFD mice and ND mice. Serum insulin concentrations were measured during the 12th week of HFD feeding. †P < 0.05; ‡P < 0.01;
*P < 0.001. HFD high-fat-diet, ND normal diet
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compared with the naive HFD or OVA-ND mice (Figs 5c,
6c), and TGF-β1 inhibition in these mice reduced AHR
but did not affect the inﬂammatory cell proﬁle of the
BALF (Fig. 5c, d).
Histological examination showed increased inﬂam-
matory cell inﬁltration in the peribronchial and peri-
vascular areas and increased goblet cell metaplasia in
the OVA-ND and OVA-HFD mice compared with the
naive ND mice (Fig. 6a–c). MT staining showed
minimally increased ﬁbrosis in the OVA-ND mice, but
anti-TGF-β mAb treatment did not affect the ﬁbrosis in
those mice. As expected, the OVA-HFD mice exhibited
enhanced ﬁbrosis compared with the OVA-ND mice.
The OVA-HFD mice receiving anti-TGF-β mAb treat-
ment exhibited attenuated lung ﬁbrosis measured by
the hydroxyproline assay and even attenuated goblet
cell hyperplasia compared with the untreated OVA-
HFD mice (Fig. 6b, c).
β
Fig. 3 AHR and inﬂammatory features of naive HFD and OVA-HFD models. AHR to MCh (a), inﬂammatory cell proﬁle in the BALF (b), IL-4 (c) and
IL-5 levels (d), and TGF-β1 (e) concentrations in lung homogenates. Immunohistochemical staining for TGF-β1 (F) in tissue from naïve HFD, OVA-HFD,
naive ND, and OVA-ND mice are shown. †P < 0.05; ‡P < 0.01; *P < 0.001. AHR airway hyperresponsiveness, MCh methacholine, BALF bronchoalveolar
lavage ﬂuid, HFD high-fat-diet, IL interleukin, OVA ovalbumin, ND normal diet, TGF transforming growth factor
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Fig. 4 Histological features of the lungs from HFD-induced obesity mice given anti-TGF-βmAb treatment. H&E, PAS, and MT staining features
(a) are shown at ×200 magniﬁcation. The collagen content of the lung tissue was measured by a hydroxyproline assay (b). Panels 4c, d show the
effects of anti-TGF-βmAb treatment on AHR to MCh (c) and the inﬂammatory cell proﬁle of the BALF (d) in naive HFD mice compared with naive ND
mice. ‡P < 0.01, *P < 0.001. HFD high-fat-diet, ND normal diet, TGF transforming growth factor, H&E hematoxylin and eosin, PAS periodic acid-Schiff,
MT Masson’s trichrome
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In vivo intranasal administration of insulin and in vitro
respiratory epithelial cell stimulation with insulin
We hypothesized that the increased insulin exposure
caused by aggravated insulin resistance in HFD mice may
induce TGF-β1 excretion from the respiratory epithelium.
Therefore, we intranasally inoculated ND mice once daily
with 20 μg of insulin for 11 days and performed anti-TGF-
β1 immunohistochemical staining and Masson’s tri-
chrome staining on the lung tissue. As expected, we found
increased TGF-β1 expression in the bronchial epithelium
and peribronchial and perivascular ﬁbrosis following the
inoculation with insulin (Fig. 7a). A quantiﬁcation of lung
ﬁbrosis with Metamorph® software also showed lung
ﬁbrosis was enhanced by repeated insulin administrations
in the ND mice (Fig. 7b). We also stimulated BEAS-2B
epithelial cells with 0.1, 1, or 10 μg/ml insulin and found
that insulin stimulation at the concentrations of 1 and
10 µg/ml signiﬁcantly enhanced TGF-β1 expression in the
bronchial epithelial cells by 24 h (Fig. 7c).
Discussion
Obesity exacerbates asthma, and asthma patients with
obesity may differ from classic asthma patients28. How-
ever, the mechanism underlying obesity’s contribution to
asthma development has not yet been completely
elucidated. In this study, we observed that HFD-induced
obesity increased insulin resistance and the expression of
TGF-β1 in the lungs, causing peribronchial and perivas-
cular pulmonary ﬁbrosis and aggravated AHR to MCh
in mice.
Several studies also have shown that mice fed a HFD
develop AHR and ﬁbrosis11,12,14,29. As the HFD did not
enhance eosinophilic or neutrophilic inﬂammation in the
lung tissue or BALF, the mechanism of AHR in obesity
seems to be quite different from that in allergic asthma. In
this study, we also measured Th2 cytokine levels in the
lung tissue, and the levels were not increased in naive
HFD mice. These results indicated that Th2-related
inﬂammation did not play an important role in HFD-
induced lung ﬁbrosis or AHR.
Pulmonary ﬁbrosis is an important pathological feature
of HFD-induced obesity in mice12,20. In this study, HFD-
induced pulmonary ﬁbrosis was conﬁrmed by MT stain-
ing of the lung tissue and a hydroxyproline assay, and the
expression of TGF-β1 was enhanced. Many studies have
demonstrated that obesity itself increases lung elastance
and may cause the peripheral airways to become more
collapsible, thereby increasing airway resistance or func-
tional residual volume. However, our study demonstrated
that HFD-induced obesity could lead to peribronchial and
Fig. 5 Anti-TGF-β1 treatment to ND or HFD mice with OVA allergic asthma model. Effects of anti-TGF-βmAb treatment on AHR to MCh and the
inﬂammatory cell proﬁle of the BALF in OVA-ND (a, b) and OVA-HFD mice (c, d). ‡P < 0.01; *P < 0.001. TGF transforming growth factor, AHR airway
hyperresponsiveness, MCh methacholine, BALF bronchoalveolar lavage ﬂuid, HFD high-fat-diet, ND normal diet, OVA ovalbumin
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perivascular ﬁbrosis, suggesting a causal relationship
between ﬁbrosis and AHR in addition to the mechanical
impairments caused by enhanced elastance. TGF-
β1 signaling has been considered the major pathogenic
mechanism for pulmonary ﬁbrosis and inﬂammatory cell
recruitment in asthma and other lung diseases16,30,31.
TGF-β1 may be involved in the differentiation of airway
smooth muscle cells32 and may alter the asthma pheno-
type, favoring a more contractile or AHR type33. There-
fore, we investigated whether the TGF-β1 pathway played
a role in HFD-induced AHR and ﬁbrosis in mice. TGF-β1
may also enhance goblet cell hyperplasia and mucus
production, which are two of the characteristic features of
asthma34,35, and our study also showed that HFD feeding
aggravated the goblet cell hyperplasia induced by OVA
sensitization and challenge. However, naive HFD mice did
not have increased mucus production by PAS staining,
suggesting that the enhanced TGF-β1 production induced
by the HFD or insulin resistance alone was not sufﬁcient
to induce goblet cell hyperplasia, but indicating the pre-
sence of the synergistic effects of TGF-β1 and Th2 cyto-
kines or the proinﬂammatory milieu in asthma. Other
inﬂammatory factors or mechanical factors in addition to
enhanced insulin resistance or TGF-β1 expression may be
required for the aggravation of goblet cell hyperplasia in
obesity-induced asthma.
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Fig. 6 Histological features of the lung tissue from OVA-HFD and OVA-ND mice given anti-TGF-β mAb treatment. H&E, PAS, and MT staining
features (a) are shown at ×200 magniﬁcation. The collagen content in lung homogenates was measured by a hydroxyproline assay (b), and the
quantiﬁcation of goblet cell hyperplasia measured by PAS staining (c) in various murine models after the inhibition of TGF-β is shown. †P < 0.05, *P <
0.001. HFD high-fat-diet, TGF transforming growth factor, H&E hematoxylin and eosin, PAS periodic acid-Schiff, MT Masson’s trichrome
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Several studies have showed that the levels of systemic
inﬂammatory markers, such as IL-6, CRP, and TNF-α, are
elevated in obesity-associated asthma11, and that the
levels of these inﬂammatory markers are also dramatically
decreased by bariatric surgery or weight reduction2,4,8,10.
As previously mentioned, we also suggested that TNF-α
produced by macrophages plays a crucial role in AHR
development in obesity-associated asthma using C57BL/6
mice;11 this mechanism may involve the induction of
TGF-β1 expression36 and insulin resistance in obesity37.
Furthermore, a HFD alone may induce neutrophilia in the
sputum, and decreased bronchodilation responses
through the activation of the Toll-like receptor pathway38,
even though we and other investigators could not ﬁnd
neutrophilic inﬂammation in an HFD-induced obesity
murine model. Obesity also increases the physiological
burden on respiration, and it may compress lung tissue,
decreasing the functional residual capacity and total lung
capacity and increasing airway resistance; these effects are
more profound in asthmatic patients, as their distal lungs
are more collapsible than those of normal subjects2. These
physiological effects cause increased breathing
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Fig. 7 Anti-TGF-β1 immunohistochemical staining and Masson’s trichrome staining after repeated intranasal inoculations of insulin. Panel
a is shown at ×200 magniﬁcation. The quantiﬁcation of the lung ﬁbrosis score calculated using Masson’s trichrome staining measured by
Metamorph® software (b) is also shown. The expression of TGF-β1 by BEAS-2B cells was dose-dependently increased by different concentrations of
insulin for different incubation times (c). TGF transforming growth factor. †P < 0.05, *P < 0.001
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requirements, possibly causing difﬁculty in the diagnosis
of true asthma39.
We also showed that treatment with a neutralizing anti-
TGF-β mAb ameliorated HFD-induced AHR, lung ﬁbro-
sis, and goblet cell hyperplasia in the OVA-induced
asthma model, which reﬂected the possible role of anti-
TGF-β treatment in asthmatic patients with obesity or
patients with severe asthma. Although asthma has been
recognized as a reversible airway obstruction, it also has
an irreversible obstructive component, especially in
steroid-intractable severe asthma or asthma associated
with obesity, and the prevention of irreversible airway
obstruction is one of the primary goals of asthma man-
agement40. However, neutralizing TGF-β did not affect
AHR and allergic inﬂammation in OVA-ND mice. These
results suggest the complexity of AHR pathogenesis and
support the hypothesis that anti-TGF-β1 treatment may
play a signiﬁcant therapeutic role, especially in asthmatic
patients with obesity. However, TGF-β1 has anti-
inﬂammatory effects, and is a key player in maintaining
the balances between tolerance to self and autoimmunity
or inﬂammatory responses to foreign antigens41, and
some studies have reported that TGF-β1 inhibition
enhances AHR and eosinophilic inﬂammation in an
allergic asthma model27,42; however, our results were not
consistent with this hypothesis. Thus, a careful approach
is required to apply this strategy for the management of
asthma.
However, the mechanism underlying obesity-induced
TGF-β1 expression is not yet known. Obesity is also
recognized as the stimulating factor for TGF-β1 expres-
sion through TNF-α36, and we already showed that obe-
sity can enhance TNF-α production by macrophages11.
Prior to participating in airway remodeling, latent TGF-β
must be cleaved into the active form; and several factors,
such as reactive oxygen species, integrins, matrix metal-
loproteinases, and insulin-like growth factor, have been
recognized as contributors to this process16,43. In this
study, we showed that HFD mice have signiﬁcant weight
gain, increased blood glucose and insulin levels, impaired
glucose tolerance, and increased insulin resistance. We
speculated that increased insulin like growth factor levels
in HFD-induced obesity mice may also increase the
conversion of latent TGF-β1 into the active form.
Immunohistochemical staining of HFD mouse tissue in
this study showed that the major source of TGF-β1
expression is the bronchial epithelium. Furthermore, we
found that exposure to insulin could induce TGF-β1
expression in bronchial epithelial cells. Immunohisto-
chemical studies in prior research previously showed that
the bronchial epithelium and submucosal cells are the
main sites of TGF-β1 production in an HFD-induced
obesity model17,27,44,45. Singh et al. reported that insulin
treatment signiﬁcantly increases the proliferation and
collagen production of airway smooth muscle cells
through the β-catenin pathway46, and insulin can also
induce collagen production by adipose tissue M2 mac-
rophages via TGF-β25. Our data and previous studies
strongly suggest that various cells may be involved in
obesity-induced asthma. Hyperglycemia or hyper-
insulinemia can also enhance cell–surface TGF-β receptor
expression through the PI3K-Akt pathway, suggesting the
possible presence of an insulin-induced autocrine TGF-β
signaling pathway23. An interaction between TGF-β1 and
insulin resistance has been reported previously. Hong
et al. reported that HFD-induced TGF-β expression pro-
vokes insulin resistance in a Drosophila obesity model21.
Those study results and our results suggest the presence
of a vicious cycle between increased insulin resistance and
TGF-β expression in obesity. Furthermore, hyper-
insulinemia in HFD-induced obesity may also mediate
bronchoconstriction through the loss of the inhibitory
effect of M2 muscarinic receptor on parasympathetic
nerves47.
This study had several limitations. First, we used male
C57BL/6 mice, as weight gain is more prominent in male
mice than in female mice. A prior study suggested that
there is a sex-speciﬁc effect of obesity on airway inﬂam-
mation, especially in adult female asthmatic patients.
Scott et al. showed that the neutrophil percentage in the
sputum correlated with BMI only in obese female asth-
matic patients, not in male obese asthmatic patients10.
This study did not examine the possible effect sex dif-
ferences may have had on our results. Second, our
research did not fully explain why severely obese subjects
without insulin resistance can have uncontrolled asthma.
We think another mechanism may be involved in that
process.
In conclusion, HFD-induced obesity causes AHR and
peribronchial and perivascular lung ﬁbrosis through the
TGF-β1 pathway, and TGF-β1 can be produced by the
bronchial epithelium via stimulation with insulin. Our
results suggest that insulin resistance may be the under-
lying cause of asthma aggravation in obesity-associated
asthma and support strategies targeting insulin resistance,
weight reduction, or anti-TGF-β1 management to treat
uncontrolled asthma in obese patients.
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